HLA-C and neoplasm: Combining TCR-T and chimeric antigen receptor (CAR) T-cell therapies shows synergistic effects by targeting distinct tumor antigens—TCR-T cells primarily recognize intracellular antigens presented by MHC, whereas CAR-T cells target surface antigens, resulting in improved therapeutic efficacy [171].